Metformin DR
Asset
Delayed-release metformin targeting the lower bowel to activate AMPK and improve glycemic control.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- AMPK signalling
- 1
- Indication
- 1,357
- Trials
- 1
- Developer
Indications
1Type 2 diabetes
Phase 3, Suspended, NCT04854512, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains6
- Owner and partners1
- Trials1,357
- Evidence for its targets6
- Competitors12
- Aging relevance2
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.